Cost-effectiveness of continuous glucose monitoring and intensive insulin therapy for type 1 diabetes.

ABSTRACT:

Background

Our objective was to determine the cost-effectiveness of Continuous Glucose Monitoring (CGM) technology with intensive insulin therapy compared to self-monitoring of blood glucose (SMBG) in adults with type 1 diabetes in the United States.

Methods

A Markov cohort analysis was used to model the long-term disease progression of 12 different diabetes disease states, using a cycle length of 1 year with a 33-year time horizon. The analysis uses a societal perspective to model a population with a 20-year history of diabetes with mean age of 40. Costs are expressed in $US 2007, effectiveness in quality-adjusted life years (QALYs). Parameter estimates and their ranges were derived from the literature. Utility estimates were drawn from the EQ-5D catalogue. Probabilities we

SUBMITTER: McQueen RB 

PROVIDER: S-EPMC3180394 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature